Hempstract, Inc. (HPST) Stock Analysis

Hempstract, Inc. (HPST) Healthcare & Pipeline Overview

Hempstract, Inc. is a US-based producer of cannabidiol (CBD) and cannabigerol (CBG) solutions, offering CBD isolate powder and distillate oil. Operating in the specialty and generic drug manufacturing sector, the company focuses on catering to the evolving market for cannabinoid-based products, while facing competition and regulatory challenges.

What Is the Investment Thesis for HPST?

Hempstract, Inc. presents a high-risk, high-reward investment opportunity within the burgeoning CBD and CBG market. The company's small market capitalization of $25.6M reflects its early stage of development and limited operational scale. Key value drivers include the increasing consumer demand for cannabinoid-based products and the potential for expansion into new therapeutic applications. However, the company's negative P/E ratio of -91.53 and a negative profit margin of -226.2% indicate significant financial challenges and the need for substantial revenue growth to achieve profitability. A gross margin of 78.8% suggests potential for profitability if sales volume increases. Upcoming catalysts include potential regulatory changes that could expand the market for CBD and CBG products. Potential risks include intense competition from established players, regulatory uncertainty, and the company's ability to secure funding for growth. The company's high beta of 1.79 indicates high volatility, making it suitable only for investors with a high-risk tolerance.

Based on FMP financials and quantitative analysis

HPST Key Highlights

Market Cap of $25.6M reflects its small size and early stage of development.

• P/E Ratio of -91.53 indicates the company is currently unprofitable.
• Profit Margin of -226.2% highlights the significant financial challenges and the need for improved efficiency.
• Gross Margin of 78.8% suggests potential for profitability if sales volume increases.
• Beta of 1.79 indicates high volatility, making it a high-risk investment.

Who Are HPST's Competitors?

HPST is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are HPST's Key Strengths?

Focus on CBD and CBG solutions.

• Offers CBD isolate powder and distillate oil.
• Operates in the growing cannabinoid market.
• High gross margin of 78.8%.

What Are HPST's Weaknesses?

Small market capitalization of $25.6M.

• Negative P/E ratio of -91.53.
• Negative profit margin of -226.2%.
• Small number of employees (2).

What Could Drive HPST Stock Higher?

Potential regulatory changes that could expand the market for CBD and CBG products.

• Increasing consumer demand for cannabinoid-based products.
• Potential for expansion into new therapeutic applications.
• Development of new product formulations.
• Strategic partnerships and acquisitions.

What Are the Key Risks for HPST?

Financial-distress signal — its Altman Z-Score of -20.88 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-42.2%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Intense competition from established players.
• Regulatory uncertainty in the CBD and CBG market.
• Potential changes in consumer preferences.
• Difficulty in securing funding for growth.
• Limited financial disclosure increases the risk of investing in HPST.

What Are the Growth Opportunities for HPST?

• Expansion into New Therapeutic Areas: Hempstract can explore opportunities to develop and market CBD and CBG-based products for specific therapeutic applications, such as pain management, anxiety relief, and sleep disorders. The market for cannabinoid-based therapeutics is projected to grow significantly as more clinical research validates their efficacy. Hempstract can partner with research institutions to conduct clinical trials and develop proprietary formulations targeting specific medical conditions. This expansion could significantly increase revenue and establish Hempstract as a leader in the cannabinoid-based therapeutics market, estimated to reach $50 billion by 2030.
• Geographic Expansion: Hempstract can expand its sales and distribution network beyond its current base in the United States. The global market for CBD and CBG products is growing rapidly, with significant opportunities in Europe, Asia, and Latin America. Hempstract can establish partnerships with international distributors or set up its own sales offices in key markets. This geographic expansion could significantly increase revenue and diversify the company's customer base. The global CBD market is projected to reach $20 billion by 2028, offering substantial growth potential for Hempstract.
• Development of New Product Formulations: Hempstract can invest in research and development to create new and innovative CBD and CBG product formulations. This could include developing new delivery methods, such as transdermal patches or inhalers, or combining CBD and CBG with other active ingredients to enhance their therapeutic effects. New product formulations can attract new customers and increase sales among existing customers. The market for innovative CBD and CBG products is growing rapidly, driven by consumer demand for more effective and convenient delivery methods. This could involve an investment of $1-2 million over the next 2 years.
• Strategic Partnerships and Acquisitions: Hempstract can pursue strategic partnerships and acquisitions to expand its product portfolio, distribution network, and market reach. This could include partnering with other CBD and CBG companies, pharmaceutical companies, or wellness product retailers. Strategic partnerships and acquisitions can accelerate growth and create synergies that enhance the company's competitive advantage. This strategy could involve acquiring smaller competitors or partnering with larger companies to gain access to new markets and technologies. The timeline for such partnerships or acquisitions could be within the next 1-3 years.
• Focus on Quality and Compliance: Hempstract can differentiate itself from competitors by focusing on producing high-quality CBD and CBG products that meet stringent regulatory requirements. This includes implementing robust quality control measures, obtaining certifications from reputable organizations, and complying with all applicable laws and regulations. A focus on quality and compliance can build trust with customers and enhance the company's reputation. This is an ongoing effort that requires continuous investment in quality control and regulatory compliance. This could involve an investment of $500,000 annually.

What Are HPST's Competitive Advantages?

• Proprietary formulations (if any).
• Brand recognition (if any).
• Strategic partnerships (if any).
• Focus on high-quality products.

What Does HPST Do?

Hempstract, Inc., formerly known as Riverdale Oil and Gas Corporation, transitioned to the production and sale of cannabidiol (CBD) and cannabigerol (CBG) solutions in November 2020. This strategic shift reflects the company's adaptation to emerging market opportunities within the healthcare sector, specifically targeting the growing demand for cannabinoid-based products. Based in Warden, Washington, Hempstract focuses on producing CBD isolate powder and distillate oil. The company's product line is geared towards consumers and businesses seeking cannabinoid ingredients for various applications, including wellness products and therapeutic formulations. Hempstract operates within the Drug Manufacturers - Specialty & Generic industry, navigating the regulatory landscape and competitive dynamics of the CBD and CBG market. The company's small size, with only two employees, indicates a lean operation, potentially relying on outsourcing or strategic partnerships for various aspects of its business, from manufacturing to distribution. As a relatively new entrant in the CBD and CBG market under the Hempstract name, the company is focused on establishing its brand presence and building customer relationships. The company's success hinges on its ability to efficiently produce high-quality CBD and CBG products, comply with regulatory requirements, and effectively market its offerings to a target audience in a competitive environment.

What Products and Services Does HPST Offer?

• Produces cannabidiol (CBD) solutions.
• Produces cannabigerol (CBG) solutions.
• Offers CBD isolate powder.
• Offers CBD distillate oil.
• Sells CBD and CBG products in the United States.
• Focuses on cannabinoid-based products for wellness and therapeutic applications.

How Does HPST Make Money?

• Produces CBD and CBG products.
• Sells products directly to consumers or businesses.
• Generates revenue through product sales.
• Focuses on high-quality cannabinoid ingredients.

What Industry Does HPST Operate In?

Hempstract, Inc. operates within the rapidly evolving CBD and CBG market, a segment of the broader Drug Manufacturers - Specialty & Generic industry. The market is characterized by increasing consumer demand for cannabinoid-based products, driven by perceived wellness benefits and expanding therapeutic applications. However, the industry faces regulatory uncertainty and intense competition from both established pharmaceutical companies and numerous smaller players. Hempstract's success depends on its ability to differentiate itself through product quality, innovation, and effective marketing strategies.

Who Are HPST's Key Customers?

• Consumers seeking CBD and CBG products for wellness.
• Businesses using CBD and CBG as ingredients in their products.
• Manufacturers of wellness products.
• Companies developing therapeutic formulations.

Return on equity for Hempstract, Inc. stands at -42.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -20.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.63 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -8.6%, the inverse of the P/E and a quick read on earnings relative to price.

Hempstract, Inc. (HPST) Valuation Context

Valued at $25.6M, HPST is classified as a micro-cap stock.

Company Profile

Hempstract, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Warden, US. The company is led by CEO Ronald M. Herzfeld. HPST has traded publicly since 2021.

Hempstract, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -20.88 places it in the distress zone, a signal of elevated financial risk.

HPST Financials

HPST Latest News

No recent news available for HPST.

What Investors Ask About Hempstract, Inc. (HPST) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources